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Summary
Background: Heart failure (HF) often accompanies chronic kidney disease (CKD) in the elderly.
This clinical condition is a critical socio-medical issue, because high-dose diuretic therapy stim-
ulates the renin—angiotensin—aldosterone axis and sympathetic nervous system outﬂow, and
may thus result in vicious cycles of cardio-renal deterioration, leading to excess hospitalization
and death. Peritoneal dialysis (PD) is a renal replacement therapy used for maintenance dial-
ysis, and is characterized by the continuous removal of ﬂuid. The present study examined the
clinical feasibility and effects of a novel style of PD for elderly CKD patients with refractory HF.
Methods: Twelve elderly CKD patients (stages 3—5) with refractory HF [New York Heart Associ-
ation (NYHA) class III, n = 9; IV, n = 3; mean age, 81± 6 years] received PD treatment. Patients
had episodes of >3 hospitalizations in the previous year, and were initially treated with ≤19
sessions of sequential hemoﬁltration, followed by incremental PD, with 3 PD sessions/week (8 h
each) at the start, increasing in frequency and dwelling time as clinically indicated.
Results: During follow-up (median, 26.5 months), PD was well tolerated by all patients, and
no patients required hospitalization for HF. Three patients died due to non-HF-related events.
All patients showed improvements in NYHA functional class (class I, n = 9; class II, n = 3) and
signiﬁcant decreases in the dose of diuretics prescribed (P < 0.05). Kidney function stabilized,
while signiﬁcant improvements in end-diastolic left ventricular diameter (−5%, P < 0.05) and
hemoglobin count (+15%, P < 0.05) were achieved. Brain natriuretic peptide (−46%) and aldos-
terone (−13%) levels tended to decrease.
Conclusions: Incremental PD could represent a novel therapeutic option for elderly patients
with refractory HF. In addition to ﬂuid removal by PD, correction of renal anemia, preservation
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of kidney function, and avoidance of high-dose diuretic therapy may play a role in maximizing
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Japan), body weight, New York Heart Association (NYHA)
functional class, echocardiographic determinants of cardiac
function, and loading conditions (EUB-8500; Hitachi Medical,clinical beneﬁts.
© 2009 Japanese College of C
ntroduction
o date, the pathophysiology and treatment options for
eart failure (HF) have been well investigated [1—5]. How-
ver, some HF patients, particularly among the elderly,
emain refractory to conventional therapies and require
requent hospitalization [6]. Furthermore, the prevalence
f HF in the population over 65 years old has been
onsistently increasing in recent years [5,6]. Very few stud-
es regarding established, evidence-based HF management
e.g. renin—angiotensin—aldosterone system (RAAS) mod-
lation, beta blockers, and aldosterone antagonists] have
ncluded elderly subjects [1—5]. Geriatric-speciﬁc issues
uch as renal insufﬁciency, anemia, and hypoalbuminemia
enerate numerous clinical difﬁculties in the treatment of
lderly HF patients, preventing or limiting the prescription
f conventional medications, and the presence of demen-
ia can lead to difﬁculties in restricting sodium intake,
atient compliance, and exclusion from invasive strategy
ptions (surgery, transplant, device therapy). These prob-
ems result in a tendency toward treatment using high-dose
iuretics [6—8]. High-dose diuretics may increase the risk
f adverse renal effects, such as exaggerating renal per-
usion (azotemia), and stimulating RAAS and sympathetic
ervous system (SNS) activity [7]. Alternative management
trategies are thus required. Extra- and/or intracorporeal
ltraﬁltrations have generated clinical improvement and
epresent potential therapeutic options for HF [8—12], but
he intermittent mode of therapy has limited the clinical
otential.
Peritoneal dialysis (PD) is a renal replacement therapy
sed for maintenance dialysis, and is characterized by the
ontinuous correction of the uremic milieu, including excess
uid in the body. PD is thus reasonably expected to bene-
t patients with HF. In fact, favorable clinical results have
ecently been reported for dialysis patients with refractory
F following the application of PD [8,10—12]. Incremental
D was ﬁrst proposed by Mehrotra et al. [13]. The therapeu-
ic concept involves prescribing the PD regimen according
o the level of residual renal function. Patients thus start
D with exchange of at least one bag, and increase PD dose
n proportion to the declining urinary excretion of solutes
nd ﬂuid. This therapeutic approach to chronic kidney dis-
ase (CKD) patients with HF may reasonably be expected to
xert cardio-renal-protective effects [14].
The present study therefore examined the clinical efﬁ-
acy and feasibility of therapeutic PD application in elderly
KD patients with HF refractory to conventional therapy.
ethodsatients
ata from 12 consecutive patients who underwent incre-
ental PD between April 2002 and May 2008 were evaluated.
T
e
D
v
cology. Published by Elsevier Ireland Ltd. All rights reserved.
atients were enrolled in this study based on the following
nclusion criteria: (1) age ≥70 years; (2) stages 3—5 CKD;
nd (3) frequent HF hospitalization (≥3 times/year) despite
onventional outpatient therapy (deﬁned as refractory HF).
lomerular ﬁltration rate (GFR) was calculated using the
odiﬁed Modiﬁcation of Diet in Renal Disease equation.
tiologies of CKD for these study subjects were not well eval-
ated, but subjects included at least two cases with diabetic
ephropathy. The major cause of CKD in the other study
ubjects was thought to be renal sclerosis, based on the
linical course. Diagnosis of HF was based on the Framing-
am or Massachusetts General Hospital criteria. The study
opulation included three patients with mild left ventricular
ystolic dysfunction [left ventricular ejection fraction (LVEF)
50%], and nine patients with preserved LVEF. All patients
ere evaluated for suitability and initiated on PD treatment
y an attending nephrologist. All patients provided written
nformed consent to participate in this study prior to enrol-
ent. All protocols were approved by the ethics committee
f our hospital.
ltraﬁltration and induction of PD
atients were initially treated with 0—19 sessions of sequen-
ial hemoﬁltration for acute decompensated HF, followed
y incremental PD. A Tenckhoff catheter was surgically
mplanted, and the optimal PD solution was determined.
ypical PD solution consisted of 1.5—2.0 L of 1.5% dex-
rose (Dianeal®; Baxter, Deerﬁeld, IL, USA) based on the
eritoneal equivalent test result and body mass. Follow-
ng completion of sequential hemoﬁltration treatments,
atients were initiated on three PD sessions/week (8 h
ach). Dwell time, frequency, dextrose concentration (1.5%,
.5%, and 4.25%), and PD solution (to icodextrin, Extraneal®;
axter) were changed as needed to optimize efﬁciency of
ltraﬁltration rate.
bservations
ime points for data analysis included the time at which
ry weight was attained (baseline), at the end of follow-up
May 2008), and/or just prior to any clinical events. Five
ndpoints were examined: all-cause mortality; cardiovascu-
ar mortality; all-cause hospitalization; HF hospitalization;
nd PD-related hospitalization.
Data collected included resting systolic and diastolic
lood pressures, heart rate (STBP-780; Omron Colin, Tokyo,okyo, Japan), such as left ventricular end-diastolic diam-
ter (LVDd), left ventricular end-systolic diameter (LVDs),
oppler measurement at left ventricular inﬂow (E/A), left
entricular ejection fraction (LVEF), renal function [serum
reatinine (Cr) and GFR], hemoglobin (Hb) level, and
Incremental PD for HF with CKD
Table 1 Baseline patient characteristics.
Variables
Age (years) 81± 6
Sex (male:female) 7:5
Diabetes mellitus (n) 3
Etiology of HF (n)
Hypertensive heart disease 6
Valvular heart disease 3
Ischemic cardiomyopathy 2
Dilated phase hypertrophic cardiomyopathy 1
Medications (n)
Angiotensin-converting enzyme inhibitors 6
Angiotensin receptor blockers 6
Beta blockers 3
Calcium channel blockers 7
Digoxin 2
Nitrate 6
New York Heart Association functional class (n)
III 9
IV 3
Data are presented as mean± standard deviation (SD) or number.
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rate, or laboratory ﬁndings were seen regarding Cr or GFR
when comparing baseline and ﬁnal data. However, a sig-
niﬁcant increase in Hb (Fig. 1B) indicated a correction ofHF, heart failure.
neurohumoral factors [brain natriuretic peptide (BNP),
plasma rennin activity (PRA) and aldosterone (ALD)].
Changes in diuretic dosages (furosemide and trichlomethi-
azide) were also recorded. An azosemide dose of 30mg was
regarded as equivalent to a furosemide dose of 20mg. HF
drugs were changed as clinically indicated. Patients with
anemia (Hb <11 g/dL) received subcutaneous epoetin-
once a week at a dose of 6000 IU and/or intravenous iron,
if appropriate.
r
n
Table 2 Status at ﬁnal dose of PD and status and major events d
Age/sex Etiology of HF PD (sessions/week)
89/F HHD 14
82/M HHD 14
85/F DHCM/Pacing 14
84/F MVR/Af/DM 14
79/M MR/Af 14
86/M HHD 7
78/M HHD 14
72/M ICM 14
71/F ICM/DM 7
79/M HHD/DM 21
79/F AR 21
76/M HHD 21
Mean± SD 14.6± 4.7
HF, heart failure; PD, peritoneal dialysis; HHD, hypertensive heart dis
mitral valve replacement; Af, atrial ﬁbrillation; DM, diabetes mellitus
AR, aortic valve regurgitation; MIA, malnutrition—inﬂammation—athero
a Patients who died.51
tatistical analysis
tatistical analysis was performed using StatView software
SAS Institute, Cary, NC, USA). Results are presented as
ean± standard deviation (SD). Student’s paired t-test was
sed to compare data between baseline and the end of
ollow-up.
esults
atient characteristics at the initiation of PD are summa-
ized in Table 1. The study population comprised elderly
atients with mild anemia and severe renal insufﬁciency.
unctional capabilities were characterized deﬁned as class
II (n = 9) or IV (n = 3). All patients were being prescribed
ngiotensin-converting enzyme inhibitors or angiotensin
eceptor blockers.
Median follow-up was 26.5 months (range, 6—62 months).
inally, mean frequency of PD sessions was 14.6± 4.7
imes/week. At the end of follow-up, one patient required
emodialysis secondary to ultraﬁltration failure of PD. None
f the patients required hospitalization due to HF, but
ne patient was hospitalized due to non-HF-related dis-
ase (colon cancer), and two patients were hospitalized
ue to uremia-related malnutritional cachexia and catheter-
elated peritonitis. All three of these hospitalized patients
ied (Table 2).
Compared with baseline values, diuretics had been with-
rawn or reduced in all patients by the end of follow-up
Table 3; Fig. 1A). No change in body weight was seen
etween baseline and ﬁnal data (Table 3).
No changes in systolic or diastolic blood pressure, heartenal anemia. In terms of echocardiographic parameters,
o changes in LVEF, LVDs, or E/A were seen, but LVDd was
uring follow-up.
Follow-up (months) Event
6 —
6 —
15 Colon cancera
21 —
22 MIA syndromea
26 —
27 —
33.5 —
33.5 Catheter-related peritonitisa
37 —
43 —
62 UF failure
27.7± 15.8
ease; DHCM, dilated-phase hypertrophic cardiomyopathy; MVR,
; MR, mitral valve regurgitation; ICM, ischemic cardiomyopathy;
sclerosis; UF, ultraﬁltration.
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Table 3 Clinical variables at baseline and on PD.
Variables Baseline On PD P
Body weight (kg) 52.1 ± 10.9 51.7 ± 12.5 0.5803
Systolic blood pressure (mmHg) 132 ± 25 133 ± 22 0.8535
Diastolic blood pressure (mmHg) 69 ± 13 69 ± 13 0.7513
Heart rate (beats/min) 72 ± 12 70 ± 7 0.4472
LV diastolic diameter (mm) 52.6 ± 5.2 48.5 ± 4.4 0.0138
LV systolic diameter (mm) 35.0 ± 6.3 31.6 ± 3.8 0.0717
LV ejection fraction (%) 56 ± 10 58 ± 6 0.4993
E/Aa 0.60 ± 0.12 0.59 ± 0.11 0.7879
Brain natriuretic peptide (pg/mL) 813.3 ± 1248.5 362.3 ± 454.2 0.0996
Aldosterone (pg/mL) 102.3 ± 52.4 87.4 ± 41.5 0.0861
Plasma renin activity (ng/mL/h) 6.7 ± 7.0 4.5 ± 4.9 0.1644
Blood urea nitrogen (mg/dL) 50.0 ± 20.0 51.6 ± 16.2 0.8276
Creatinine (mg/dl) 4.6 ± 2.1 5.2 ± 2.4 0.2073
Calcium (mequiv./L) 8.6 ± 0.8 8.3 ± 0.7 0.2742
Phosphate (mequiv./L) 4.9 ± 1.1 3.8 ± 1.2 0.3106
Albumin (g/dL) 2.9 ± 0.5 2.6 ± 0.5 0.0566
Total cholesterol (mg/dL) 163 ± 57 157 ± 35 0.7116
Hemoglobin (g/dL) 9.8 ± 1.7 11.0 ± 1.3 0.0364
Estimated GFR (mL/min/1.73 m2) 10.5 ± 8.2 9.5 ± 7.5 0.2476
Furosemide dosage (mg) 56.7 ± 30.6 20.0 ± 19.1 0.0056
Trichlomethiazide dosage (mg) 2.3 ± 1.9 0.8 ± 1.3 0.0121
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a n = 9 (not available for three cases; two cases of atrial ﬁbrillat
igniﬁcantly decreased (Fig. 1C). Decreases in BNP, PRA, and
LD were identiﬁed, but did not reach the level of statisti-
al signiﬁcance. Summarized data are presented in Table 3.
inal NYHA functional class improved in all cases (class I,
= 9; class II, n = 3; Fig. 1D).
iscussion
D was used to treat 12 elderly patients with CKD and
efractory HF. PD was well tolerated by all patients dur-
ng the observation period and produced clinical beneﬁts
s demonstrated by (1) improved NYHA functional class;
2) no hospitalization related to HF; (3) reduced dosages
f diuretics; (4) increased Hb level; (5) decreased LV dias-
olic diameter; (6) no worsening in neurohumoral factor
evels; and (7) maintenance of cardiac and renal func-
ion.
PD may exert therapeutic effects in the context of
F via several mechanisms, such as removing excess
ater and sodium [8,10—12]. The sodium excretion efﬁ-
iency of PD is known to be nearly 1.5-fold higher than
hat of the same volume of urine [15]. In this study,
edian removal of excess water and sodium per PD ses-
ion was 213mL and 134mequiv./L, respectively (data
ot shown). This is equivalent to a 1.4 g reduction in
odium per PD session, without the need for high-dose
iuretics. Although extracorporeal ultraﬁltration is supe-
ior to PD in terms of the prompt removal of excess
ater and sodium, the property of continuous and slow
emoval of excess water and sodium by PD could contribute
o the maintenance of renal function and avoidance of
dverse renal effects [7]. Furthermore, PD does not require
c
p
l
icular; GFR, glomerular ﬁltration rate; E/A, Doppler measurement
ne case of right ventricular apical pacing).
ospitalization, contrasting sharply with the extracorpo-
eal ultraﬁltration method. This may also beneﬁt elderly
atients.
Regarding the therapeutic beneﬁts of increased ultraﬁl-
ration volume in patients with HF, the pathophysiological HF
rocess could be at least partially reversed by inhibition of
nﬂammatory cytokine release, normalization of neurohor-
onal pathways, and restoration of diuretic responsiveness
16—20]. As ultraﬁltration-mediated convective clearance
f cytokines is nonspeciﬁc, beneﬁcial cytokines are lost
long with harmful ones. Furthermore, although the mass
learance of cytokine compounds with PD is low, PD can
emove the molecular weight of myocardial depressant fac-
ors, which range between 0.5 and 20 to 30 kDa (e.g. tumor
ecrosis factor-). In this and previous studies, the observa-
ion that PD resulted in decreased BNP (3.5 kDa) levels [17]
as very important from a clinical perspective, although this
ecreasing tendency was not signiﬁcant. The decrease in
NP might also be due to a reduction in cardiac preload and
ay affect changes in cognitive function, warranting further
nvestigation.
Anemia is prevalent in both HF and CKD. In fact, these
hree conditions form a vicious cycle, with each condi-
ion capable of causing or being caused by the others.
his phenomenon has been referred to as cardio-renal
nemia syndrome by Silverberg et al. [20—23]. While sev-
ral studies have suggested that erythropoietin therapy
ight be beneﬁcial in CKD patients with HF, this remains
ontroversial, as many patients appear unresponsive. The
resent study revealed signiﬁcant increases in hemoglobin
evels following PD induction (Table 3). With no change in
nﬂammatory conditions, increased responsiveness to ery-
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Figure 1 Changes in furosemide dosage (A), hemoglobin (Hb) level (B), and left ventricular diastolic diameter (LVDd) (C). Lines
within boxes represent median values, with top and bottom lines of boxes representing the 75th and 25th percentiles, respectively,
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reduced furosemide dosing, reduced LVDd, higher Hb, and better
as mean± SD. PD, peritoneal dialysis; NYHA, New York Heart As
thropoietin administration as well as glucose-calorie load
by PD solution may be involved in these improvements.
In the present study, two cases were lost to PD-related
complications. One patient died due to uremia-related
malnutritional cachexia, which is common among elderly
patients on chronic dialysis. This characteristic clini-
cal feature has recently been deﬁned as malnutrition—
inﬂammation—atherosclerosis (MIA) syndrome, and accumu-
lated evidence has revealed the worst outcomes in patients
with this syndrome [24]. In this patient, the cause of
death was diagnosed as malnutrition and cachexia due to
pathology-related uremic condition. The other patient died
due to catheter-related peritonitis. Complications of PD
include catheter-related infections such as exit-site infec-
tion, skin-tunnel (subcutaneous) infection and peritonitis,
and mechanical stress-related events involving the PD solu-
tion, such as herniation of the esophagus, abdominal wall,
or inguinal region. Among these, catheter-related infec-
tion is the most common complication according to recent
reports [24]. The peritonitis rate in Japan is low com-
pared with other countries, at one episode per 37.0—58.8
patient—months. As a reason for dropout from PD, peritoni-
tis accounts for only 14% of dropouts in Japan [25]. The
case in our study was well managed by PD for 33.5 months,
and was free from peritonitis before the ﬁnal episode. In
addition, catheter-related peritonitis is usually curable, and
Rnd 10th percentiles, respectively. Incremental PD resulted in
York Heart Association functional class (D). Data are presented
tion.
anagement is well established using standard antibiotic
egimens. However, in the case of an elderly patient with MIA
yndrome, episodes of peritonitis can sometimes become
ethal. The case in the present study should be the same
linical conditions as mentioned above.
We think that this novel approach of incremental PD could
e beneﬁcial, since no subjects needed hospitalization due
o HF during the study, in striking contrast to the pre-PD
eriod for all subjects. However, some limitations in this
tudy must be considered when interpreting the results.
irst, the number of patients was limited, and the study
esign was observational and not randomized or compared
o untreated controls. These are issues that need to be
ddressed in future studies.
In conclusion, incremental PD could represent a novel
herapeutic option for elderly patients with refractory HF. In
ddition to ﬂuid removal by PD, correction of renal anemia,
reservation of kidney function, and avoidance of high-dose
iuretic therapy may play roles in maximizing the clinical
eneﬁts of therapy. Further investigations are needed to
etermine whether these results apply to all types of HF.eferences
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